Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+3.62%
-2.90%
+0.46%
-1.28%
CRNX
Crinetics Pharmaceuticals
$45.91
Login to display Crinetics Pharmaceuticals (CRNX) recommendation from the last 90 days from financial news and social media. Strengths
Upgraded on attractively valued
Risk Analysis
Trading above its fair value
Technical Indicators
Overbought
Chart
$33.3 (+37.87%)
$29.06 (+57.98%)
$31.39 (+46.26%)
$53.14 (-13.61%)
CRNX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
CRNX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading above its fair value
CRNX Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRNX Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayCRNX Earnings
The TTM reflects 12-month period, providing review of CRNX financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is CRNX current stock price?
What are CRNX stock strengths?
What risks are associated with CRNX stock?
When is CRNX next earnings report?
What is CRNX market cap and volume?
What is CRNX's current Stock IQ?
Should I buy CRNX stock right now?
Is CRNX a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRNX?
What does a 'Strong Sell' rating mean for CRNX?
What factors influence CRNX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.62%
-2.90%
+0.46%
-1.28%
CRNX
Crinetics Pharmaceuticals
Current Price
$45.91
Stock Insights
Strengths
Upgraded on attractively valued
Risk Analysis
Trading above its fair value
Technical Indicators
Overbought
Login to view Crinetics Pharmaceuticals (CRNX) recommendation from the last 90 days from financial news and social media.
Chart
$33.3 (+37.87%)
$29.06 (+57.98%)
$31.39 (+46.26%)
$53.14 (-13.61%)
CRNX Analysts Opinion
CRNX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading above its fair value
CRNX Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRNX Street view is extremely bullish and have positive views on the near-term outlook
CRNX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayCRNX Earnings
The TTM data reflects the most recent 12-month period, providing overview of CRNX financial performance.
CRNX Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
CRNX Latest Analysis
Baird Maintains Crinetics Pharmaceuticals (CRNX) Outperform Recommendation. Fintel reports that on September 26 2025 Baird maintained coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Outperform recommendation. Analyst Price Forecast Suggests 102.39% Upside
Today
JMP Securities Maintains Crinetics Pharmaceuticals (CRNX) Market Outperform Recommendation. Fintel reports that on September 26 2025 JMP Securities maintained coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Market Outperform recommendation. Analyst Price Forecast Suggests 102.39% Upside
Today
Crinetics: FDA Approval And Expansion Of Palsonify In Focus Maintaining Buy Rating.
Today
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts. Throughout the last three months 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: ) offering a diverse set of opinions from ish to bearish.Summarizing their recent assessments the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.0400002000010000100000000Analysts have set 12-month price targets for Crinetics Pharmaceuticals revealing an average target o
Today
FDA Approves Crinetics Pharmas First Daily Pill For Rare Growth Disorder. On Thursday the United States Food and Drug Administration (FDA) approved ) Palsonify (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom .Acromegaly is a rare disorder characterized by the excessive production of growth hormone (GH) leading to abnormal growth of hands feet and facial features in adults.Palsonify a selectively-targeted somatostatin
Today
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism. Shares of Crinetics Pharmaceuticals surged Friday after the Food and Drug Administration approved the companys acromegaly drug Palsonify.The post Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism appeared first on Investor'.s Business Daily.
Today
Crinetics Pharmaceuticals BlackBerry Perpetua Resources And Other Big Stocks Moving Higher On Friday. United States stocks were higher with the Dow Jones index gaining more than 200 points on Friday.Shares of ) rose sharply during Friday'.s session after the FDA Also Baird and JMP Securities raised their respective price targets on the stock.Crinetics Pharmaceuticals shares jumped 23.7% to $44.41 on Friday.Here are some other big stocks recording gains in today’.s session.) gained 21.2%
Today
Crinetics wins FDA approval for acromegaly therapy.
Today
Crinetics Pharma: FDA Approves PALSONIFY First Daily Pill For Acromegaly . (RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) announced that the United States Food and Drug Administration has approved PALSONIFY (paltusotine) as a first-line treatment for adults with acromegaly who have not responded adequately to surgery or for whom surgery is not an option.
Today
Crinetics stock rating reiterated at Overweight by Cantor Fitzgerald.
Today
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRNX Stock trends
CRNX Stock performance
CRNX Stock analysis
CRNX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Latest Updates
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings